State of the Art Reviews: Male Menopause: Fact or Fiction?

American Journal of Lifestyle Medicine

Volumn 2, Issue 2, 2008, Pages 132-141

  Wald, Moshe ^a   Miner, Martin ^b   Seftel, Allen D ^c  

^a UNIVERSITY OF IOWA   (United States)

^b BROWN UNIVERSITY   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

aging; andropause; hypogonadism; male; testosterone

Indexed keywords

EID: 84990366373     PISSN: 15598276     EISSN: None     Source Type: Journal    
DOI: 10.1177/1559827607311513     Document Type: Review

References (99)

1. Hafez B., Hafez ESE. Andropause: endocrinology, erectile dysfunction, and prostate pathophysiology. Arch Androl. 2004; 50: 45-68.
2. Tariq SH, Haren MT, Kim MJ, et al. Andropause: is the emperor wearing any clothes? Rev Endocrinol Metab Disord. 2005; 6: 77-84.
3. Matsumoto AM Andropause: clinical implication of the decline in serum testosterone levels with aging in men. J Gerontol Med Sci. 2002; 57A: M76-M99.
4. Morley JE Hormones and the aging process. J Am Geriatr Soc. 2003; 51(suppl S): S333-S337.
5. Blazer DG Depression in late life: review and commentary. J Gerontol Med Sci. 2003; 58A: 249-265.
6. Myers JB, Meacham RB Androgen replacement therapy in the aging male. Rev Urol. 2003; 5: 216-226.
7. Lund BC, Bever-Stille KA, Perry PJ Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men. Pharmacotherapy. 1999;19: 951-956.
8. Vermeulen A. Androgens and the aging male. J Clin Endocrinol Metab. 1999; 73: 221-224.
9. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001; 86: 724-731.
10. Morley JE, Kaiser FE, Perry HM III, et al. Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men. Metabolism. 1997; 46: 410-413.
11. Feldman HA, Longcope C., Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002; 87: 589-598.
12. Leifke E., Gorenoi V., Wichers C., et al. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clin Endocrinol. 2000; 53: 689-695.
13. Kaiser FE, Viosca SP, Morley JE, et al. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc. 1988; 36: 511-519.
14. Neaves WB, Johnson L., Porter JC, et al. Leydig cell numbers, daily sperm production, and serum gonadotropin levels in aging men. J Clin Endocrinol Metab. 1984; 55: 756-763.
15. Gray A., Feldman HA, McKinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 1991; 73: 1016-1025.
16. Deslypere JP, Vermeulen A. Leydig cell function in normal men: the effect of age, life-style, residence, diet, and activity. J Clin Endocrinol Metab. 1984; 59: 955-962.
17. Winters SJ, Troen P. Episodic luteinizing hormone (LH) secretion and the response of LH and follicle-stimulating hormone to LH-releasing hormone in aged men: evidence for a coexistent primary testicular insufficiency and an impairment in gonadotropin secretion. J Clin Endocrinol Metab. 1984; 55: 560-565.
18. Tenover JS, Bremner WJ Circadian rhythm of serum immunoreactive inhibin in young and elderly men. J Gerontol Med Sci. 1991; 46: M181-M184.
19. Winters SJ, Atkinson L. Serum LH concentrations in hypogonadal men during transdermal testosterone replacement through scrotal skin: further evidence that ageing enhances testosterone negative feedback. The Testoderm Study Group. Clin Endocrinol. 1997; 47: 314-322.
20. Keenan DM, Veldhuis JD Disruption of the hypothalamic luteinizing hormone pulsing mechanism in aging men. Am J Physiol Regul Integr Comp Physiol. 2001; 281: R1917-R1924.
21. Korenman SG, Morley JE, Mooradian AD, et al. Secondary hypogonadism in older men: its relation to impotence. J Clin Endocrinol Metab. 1990; 71: 963-969.
22. Veldhuis JD, Iranmanesh A., Keenan DM Erosion of endogenous testosterone-driven negative feedback on pulsatile luteinizing hormone secretion in healthy aging men. J Clin Endocrinol Metab. 2004; 89: 5753-5761.
23. Bremner WJ, Vitiello MV, Prinz PN Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56: 1278-1281.
24. Brawer MK Testosterone replacement in men with andropause: an overview. Rev Urol. 2004; 6: S9-S15.
25. Institute of Medicine. Testosterone and Aging: Clinical Research Directions. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Washington, DC: National Academies Press; 2003.
26. Gladh YM, Rahgozar M., Hammar ML, et al. Prevalence of symptoms possibly related to PADAM, in a Swedish population aged 55, 65 and 75 years. Maturitas. 2005; 50: 161-166.
27. Mulligan T., Frick MF, Zuraw QC, Stemhagen A., McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006; 60: 762-769.
28. Araujo AB, O'Donnell A., Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004; 89: 5920-5926.
29. Szulc P., Claustrat B., Marchand F., Delmas PD Increased risk of falls and increased bone resorption in elderly men with partial androgen deficiency: the MINOS study. J Clin Endocrinol Metab. 2003; 88: 5240-5247.
30. Miner MM, Seftel AD Testosterone and aging: what have we learned since the Institute of Medicine report and what lies ahead? Int J Clin Pract. 2007; 61: 622-632.
31. Heaton JPW. Hormone treatments and preventive strategies in the aging male: whom and when to treat? Rev Urol. 2003; 5: S16-S21.
32. Morales A., Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males: official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male. 2002; 5: 74-86.
33. Morales A., Heaton JPW. Hormonal erectile dysfunction: evaluation and management. Urol Clin North Am. 2001; 28: 279-288.
34. Alexander GM, Swerdloff RS, Wang C., et al. Androgen behavior correlations in hypogonadal and eugonadal men: cognitive abilities. Horm Behav. 1998; 33: 85-94.
35. Urban RJ, Bodenburg YH, Gilkison C., et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol. 1995; 269: E820-E826.
36. Tenover JS Androgen administration to aging men. Endocrinol Metab Clin North Am. 1994; 23: 877-892.
37. Hibberts NA, Howell AE, Randall VA Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. J Endocrinol. 1998;156: 59-65.
38. Garaulet M., Perex-Llamas F., Fuente T., Zamora S., Tebar FJ Anthropometric, computed tomography and fat cell data in an obese population: relationship with insulin, leptin, tumor necrosis factor-alpha, sex hormone-binding globulin and sex hormones. Eur J Endocrinol. 2000; 143: 657-666.
39. Behre HM, Kliesch S., Leifke E., Link TM, Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997; 82: 2386-2390.
40. Youngstedt SD, Kripke DF, Elliott JA, Klauber MR Circadian abnormalities in older adults. J Pineal Res. 2001; 31: 264-272.
41. Makhsida N., Shah J., Yan G., Fisch H., Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005; 174: 827-834.
42. Basaria S., Muller DC, Carducci MA, Egan J., Dobs AS Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006;106: 581-588.
43. Smith MR, Lee H., Nathan DM Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91: 1305-1308.
44. Corrales JJ, Burgo RM, Garca-Berrocal B., et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism. 2004; 53: 666-672.
45. Fukui M., Kitagawa Y., Nakamura N., et al. Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care. 2003; 26: 1869-1873.
46. Betancourt-Albrecht M., Cunningham GR Hypogonadism and diabetes. Int J Impot Res. 2003; 15: S14-S20.
47. Niskanen L., Laaksonen DE, Punnonen K., Mustajoki P., Kaukua J., Rissanen A. Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes Obes Metab. 2004; 6: 208-215.
48. Boyanov MA, Boneva Z., Christov VG Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003; 6: 1-7.
49. Kapoor D., Goodwin E., Channer KS, Jones TH Testosterone replacement reduces insulin resistance in hypogonadal men with type 2 diabetes [abstract P1-394]. Paper presented at: 87th Annual Meeting of the Endocrine Society, ENDO 2005; June 4-7, 2005; San Diego, CA.
50. Liu PY, Yee B., Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab. 2003; 88: 3605-3613.
51. Malkin CJ, Pugh PJ, Jones RD, Kapoor D., Channer KS, Jones TH The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004; 89: 3313-3318.
52. Pagotto U., Gambineri A., Pelusi C., et al. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003; 88: 4139-4143.
53. Steidle C., Schwartz S., Jacoby K., et al. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab. 2003; 88: 2673-2681.
54. Crawford BA, Liu PY, Kean MT, Bleasel JF, Handelsman DJ Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab. 2003; 88: 3167-3176.
55. Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab. 2004; 89: 503-510.
56. Page ST, Amory JK, Bowman FD, et al. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T. J Clin Endocrinol Metab. 2005;90: 1502-1510.
57. Magno C., Anastasi G., Morabito N., et al. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate. Eur Urol. 2005; 47: 575-580.
58. Boxer RS, Kenny AM, Dowsett R., Taxel P. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer. Aging Male. 2005; 8: 207-212.
59. Lee H., Finkelstein JS, Miller M., Comeaux SJ, Cohen RI, Leder BZ Effects of selective testosterone and estradiol withdrawal on skeletal sensitivity to parathyroid hormone in men. J Clin Endocrinol Metab. 2006; 91: 1069-1075.
60. Barqawi A., O'Donnell C., Kumar R., Koul H., Crawford ED Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res. 2005; 17: 370-374.
61. Schmidt PJ, Berlin KL, Danaceau MA, et al. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry. 2004; 61: 997-1004.
62. Seftel AD, Mack RJ, Secrest AR, Smith TM Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning. J Androl. 2004; 25: 963-972.
63. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-dependent effects of testosterone on sexual function, mood, and visuospatial cognition in older men. J Clin Endocrinol Metab. 2005; 90: 3838-3846.
64. Wang C., Cunningham G., Dobs A., et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004; 89: 2085-2098.
65. Rosenthal BD, May NR, Metro MJ, Harkaway RC, Ginsberg PC Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology. 2006; 67: 571-574.
66. Shabsigh R., Kaufman JM, Steidle C., Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2004;172: 658-663.
67. Isidori AM, Gianette E., Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005; 63: 280-293.
68. Jones RD, Nettleship JE, Kapoor D., Jones HT, Channer KS Testosterone and atherosclerosis in aging men: purported association and clinical implications. Am J Cardiovasc Drugs. 2005; 5: 141-154.
69. Muller M., van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004; 109: 2074-2079.
70. Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004; 90: 871-876.
71. Wald M., Meacham RB, Ross LS, Niederberger CS Testosterone replacement therapy for older men. J Androl. 2006; 27: 126-132.
72. American Society of Andrology. Testosterone replacement therapy for male aging. December 2004. Available at: http://www.andrologysociety.com/positionstatements. Accessed April 23, 2007.
73. Morales A., Lunenfeld B. Investigation, treatment and monitoring of late-onset hypodonadism in males: official recommendations of ISSAM. Aging Male. 2002; 5: 74-86.
74. Bhasin S., Bremner WJ Emerging issues in androgen replacement therapy. J Clin Endocrinol Metab. 1997; 82: 3-8.
75. Jockenhovel F. Testosterone supplementation: what and how to give. Aging Male. 2003; 6: 200-206.
76. Yu Z., Gupta SK, Hwang SS, et al. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. J Clin Pharmacol. 1997; 37: 1139-1145.
77. Korbonits M., Kipnes M., Grossman AB Striant SR: a novel, effective and convenient testosterone therapy for male hypogonadism. Int J Clin Pract. 2004; 58: 1073-1080.
78. Wang C., Swerdloff R., Kipnes M. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab. 2004; 89: 3821-3829.
79. Rhoden EL, Morgentaler A. Medical progress: risks of Testosterone replacement therapy and recommendations for monitoring. N Engl J Med. 2004; 350: 482-492.
80. Meikle AW, Dobs AS, Adolfsson J., et al. Prostate size in hypogonadal men treated with nonscrotal permeation-enhanced testosterone transdermal system. Urology. 1997; 49: 191-196.
81. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol A Biol Sci Med Sci. 2001; 56: M266-M272.
82. Sih R., Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997; 82: 1661-1667.
83. Dobs AS, Meikle AW, Arver S., et al. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with biweekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999; 84: 3469-3478.
84. Comhaire FH Andropause: hormone replacement therapy in the aging male. Eur Urol. 2000; 38: 655-662.
85. Krieg M., Nass R., Tunn S. Effect of aging on endogenous level of 5(alpha)-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab. 1993;77: 375-381.
86. Pechersky AV, Mazurov VI, Semiglazov VF, et al. Androgen administration in middle-aged and ageing men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int J Androl. 2002; 25: 119-125.
87. Marcelli M., Cunningham GR Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab. 1999;84: 3463-3468.
88. Curran MJ, Bihrle W. III. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology. 1999; 53: 423-424.
89. Loughlin KR, Richie JP Prostate cancer after exogenous testosterone treatment for impotence. J Urol. 1997; 157: 1845.
90. Slater S., Oliver RTD. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging. 2000; 17: 431-439.
91. Carter HB, Pearson JD, Metter EJ, et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate. 1995;27: 25-31.
92. Heikkila R., Aho K., Heliovaara M., et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999; 86: 312-315.
93. Hsing AW Hormones and prostate cancer: what's next? Epidemiol Rev. 2001; 23: 42-58.
94. Gustafsson O., Norming U., Gustafsson S., et al. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population. Br J Urol. 1996; 77: 433-440.
95. Vermeulen A. Androgen replacement therapy in the aging male: a critical evaluation. J Clin Endocrinol Metab. 2001; 86: 2380-2390.
96. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients-2002 update. Endocr Pract. 2002; 8: 440-456.
97. Morgentaler A., Rhoden EL Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/ml or less. Urology. 2006; 68: 1263-1267.
98. Bhasin S., Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2006; 91: 1995-2010.
99. Vermeulen A. Hormonal cut-offs of partial androgen deficiency: a survey of androgen assays. J Endocrinol Invest. 2005; 28(suppl 3):28-31.